interferon alfa-2b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5205	98530-12-2

Description:

Molecule	Description
Synonyms: interferon alfa-2b intron A interferon alfa-2b recombinant	Interferon alfa-2b is an alpha interferon and is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. In vitro studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells. Interferon alfa via inhalation is included in national guidelines from China as a possible option for treatment of COVID-19. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

interferon alfa-2b
intron A
interferon alfa-2b recombinant

Interferon alfa-2b is an alpha interferon and is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. In vitro studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells. Interferon alfa via inhalation is included in national guidelines from China as a possible option for treatment of COVID-19.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2	MU	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 4, 1986	FDA	SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Influenza like illness	61.92	19.28	41	3437	66783	63418761
Product use in unapproved indication	60.66	19.28	61	3417	179019	63306525
Depression	33.23	19.28	47	3431	196445	63289099
Bladder cancer recurrent	33.15	19.28	6	3472	155	63485389
Metastatic malignant melanoma	29.76	19.28	8	3470	1307	63484237
Hypothyroidism	29.73	19.28	22	3456	42610	63442934
Fatigue	28.12	19.28	109	3369	887919	62597625
Anaemia	27.72	19.28	54	3424	293376	63192168
Fibrinolysis	27.47	19.28	4	3474	24	63485520
Decreased appetite	25.92	19.28	48	3430	251004	63234540
Nausea	24.70	19.28	102	3376	854369	62631175
Hyperthyroidism	24.01	19.28	13	3465	14660	63470884
Platelet count decreased	22.97	19.28	30	3448	116092	63369452
Cutaneous sarcoidosis	22.61	19.28	5	3473	362	63485182
Respiratory papilloma	21.42	19.28	3	3475	13	63485531
Hypophosphataemia	21.17	19.28	11	3467	11415	63474129
Product dose omission issue	20.75	19.28	42	3436	234271	63251273
Hepatitis B surface antibody positive	20.24	19.28	4	3474	167	63485377
Hepatitis B core antibody positive	19.40	19.28	4	3474	207	63485337
Retinal exudates	19.28	19.28	5	3473	711	63484833

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Influenza like illness	111.63	18.27	60	4585	27574	34924712
Product use in unapproved indication	63.51	18.27	78	4567	117421	34834865
Retinopathy	57.62	18.27	18	4627	2046	34950240
Osteonecrosis	43.01	18.27	26	4619	14864	34937422
Retinal exudates	40.77	18.27	11	4634	745	34951541
Fatigue	40.36	18.27	124	4521	370529	34581757
Hepatic cancer	39.15	18.27	20	4625	8255	34944031
Vogt-Koyanagi-Harada disease	37.55	18.27	7	4638	84	34952202
Optic nerve sheath haemorrhage	31.71	18.27	4	4641	0	34952286
Injection site necrosis	31.40	18.27	8	4637	433	34951853
Retinal haemorrhage	29.12	18.27	14	4631	5075	34947211
Bladder cancer recurrent	27.17	18.27	7	4638	396	34951890
Myelodysplastic syndrome	25.85	18.27	21	4624	19187	34933099
Portal tract inflammation	25.72	18.27	5	4640	76	34952210
Depression	25.50	18.27	46	4599	97052	34855234
Decreased appetite	25.26	18.27	63	4582	166329	34785957
Injection site ulcer	24.94	18.27	6	4639	256	34952030
Chills	24.68	18.27	41	4604	81002	34871284
Adverse event	24.06	18.27	20	4625	18857	34933429
Restrictive cardiomyopathy	23.20	18.27	7	4638	708	34951578
Pneumoconiosis	20.46	18.27	5	4640	228	34952058
Disease recurrence	19.89	18.27	19	4626	21471	34930815
Pyrexia	19.84	18.27	92	4553	332921	34619365
Blood phosphorus decreased	18.96	18.27	9	4636	3172	34949114
White blood cell count decreased	18.71	18.27	40	4605	95405	34856881
Haemolytic uraemic syndrome	18.48	18.27	8	4637	2278	34950008

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Influenza like illness	101.84	15.34	70	7308	71637	79665373
Product use in unapproved indication	81.93	15.34	108	7270	250251	79486759
Retinopathy	60.73	15.34	20	7358	3871	79733139
Bladder cancer recurrent	59.78	15.34	13	7365	510	79736500
Retinal exudates	53.44	15.34	14	7364	1221	79735789
Osteonecrosis	50.45	15.34	33	7345	31062	79705948
Depression	48.22	15.34	78	7300	216712	79520298
Vogt-Koyanagi-Harada disease	44.74	15.34	9	7369	240	79736770
Hepatic cancer	41.44	15.34	20	7358	10509	79726501
Retinal haemorrhage	39.74	15.34	18	7360	8199	79728811
Myelodysplastic syndrome	34.75	15.34	26	7352	30275	79706735
Decreased appetite	33.80	15.34	88	7290	342330	79394680
Anaemia	31.96	15.34	102	7276	444913	79292097
Fatigue	31.62	15.34	169	7209	929558	78807452
Platelet count decreased	31.55	15.34	61	7317	194603	79542407
Metastatic malignant melanoma	30.26	15.34	11	7367	2852	79734158
Disease recurrence	30.04	15.34	28	7350	44081	79692929
Injection site necrosis	28.82	15.34	9	7369	1469	79735541
White blood cell count decreased	25.75	15.34	55	7323	188233	79548777
Injection site ulcer	25.66	15.34	7	7371	712	79736298
Portal tract inflammation	25.13	15.34	5	7373	126	79736884
Hypophosphataemia	24.89	15.34	18	7360	19895	79717115
Pyrexia	24.12	15.34	125	7253	678584	79058426
Cutaneous sarcoidosis	23.57	15.34	6	7372	467	79736543
Restrictive cardiomyopathy	23.32	15.34	7	7371	1001	79736009
Therapy non-responder	22.96	15.34	35	7343	92270	79644740
Glomerulosclerosis	22.59	15.34	7	7371	1115	79735895
Haemolytic uraemic syndrome	22.32	15.34	10	7368	4439	79732571
Disease progression	21.99	15.34	51	7327	184311	79552699
Pneumoconiosis	21.95	15.34	5	7373	243	79736767
Basedow's disease	21.75	15.34	5	7373	253	79736757
Fibrinolysis	20.53	15.34	4	7374	90	79736920
Off label use	19.59	15.34	147	7231	907068	78829942
Blood lactate dehydrogenase increased	19.54	15.34	21	7357	39149	79697861
Hypothyroidism	19.26	15.34	24	7354	52368	79684642
Raynaud's phenomenon	18.91	15.34	6	7372	1032	79735978
Blood phosphorus decreased	18.48	15.34	10	7368	6658	79730352
Refractory anaemia with ringed sideroblasts	18.28	15.34	3	7375	24	79736986
Respiratory papilloma	18.17	15.34	3	7375	25	79736985
Drug hypersensitivity	18.03	15.34	3	7375	298913	79438097
Hepatic fibrosis	17.66	15.34	10	7368	7270	79729740
Nausea	17.33	15.34	149	7229	957047	78779963
Coagulation factor V level decreased	17.31	15.34	5	7373	626	79736384
Alanine aminotransferase increased	17.26	15.34	43	7335	162527	79574483
Aspartate aminotransferase increased	17.24	15.34	39	7339	138602	79598408
Heart transplant	16.82	15.34	6	7372	1475	79735535
Biopsy muscle abnormal	16.62	15.34	3	7375	44	79736966
Chromosome analysis abnormal	16.59	15.34	4	7374	249	79736761
Hepatitis C RNA positive	16.59	15.34	4	7374	249	79736761
Hepatitis B surface antibody positive	16.27	15.34	4	7374	270	79736740
Liver transplant	16.20	15.34	8	7370	4415	79732595
Immune thrombocytopenia	15.51	15.34	13	7365	17792	79719218
Hepatitis C	15.41	15.34	11	7367	11914	79725096

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L03AB05	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Interferons
FDA CS	M0025711	Interferon-alpha
FDA EPC	N0000175521	Interferon alpha
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000998	Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Follicular lymphoma	indication	55150002
Chronic type B viral hepatitis	indication	61977001
Hairy cell leukemia	indication	118613001
Chronic hepatitis C	indication	128302006
Condyloma acuminatum	indication	240542006	DOID:11168
Malignant melanoma	indication	372244006
Kaposi's sarcoma associated with AIDS	indication	420524008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
43K1W2T1M6	UNII
4018794	VANDF
4021035	VANDF
4022538	VANDF
C0002199	UMLSCUI
CHEMBL1201558	ChEMBL_ID
CHEMBL2107842	ChEMBL_ID
71306834	PUBCHEM_CID
DB00105	DRUGBANK_ID
D02745	KEGG_DRUG
D000077190	MESH_DESCRIPTOR_UI
DB15131	DRUGBANK_ID
2420	MMSL
2428	MMSL
4892	MMSL
d01369	MMSL
003424	NDDF
108797002	SNOMEDCT_US
386915008	SNOMEDCT_US
545290	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1133	INJECTION, SOLUTION	19.20 ug	SUBCUTANEOUS	BLA	26 sections
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1133	INJECTION, SOLUTION	19.20 ug	SUBCUTANEOUS	BLA	26 sections
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1133	INJECTION, SOLUTION	19.20 ug	SUBCUTANEOUS	BLA	26 sections
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1168	INJECTION, SOLUTION	11.60 ug	SUBCUTANEOUS	BLA	26 sections
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1168	INJECTION, SOLUTION	11.60 ug	SUBCUTANEOUS	BLA	26 sections
INTRON A	HUMAN PRESCRIPTION DRUG LABEL	1	0085-1168	INJECTION, SOLUTION	11.60 ug	SUBCUTANEOUS	BLA	26 sections